ARCHIVES

Tyrosine Kinase Inhibitor Encoraging For NSCLC

This article is from The Cancer Letter archive.

Vol. 24 No. 7 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

August 19, 1994

In Brief: Waxman Now Key House Health Figure; Kennedy Subcommittee Beefed Up with Top Democrats

February 9, 1979

Bonadonna’s Study At Four Years: CMF Group Still Doing Better

November 24, 1978

Phase II Study Of Pfizer Drug Meets Primary Endpoint

April 24, 2009

Board Defers core Guideline changes, Asks Subcommittee For Alternate Plans

November 18, 1977

HEW Says Patent Delays Temporary

August 25, 1978